The global synthetic biology market was valued at USD 16.2 billion in 2024 and is projected to reach USD 42.06 billion by 2030, expanding at a CAGR of 17.30% from 2025 to 2030. Growth is driven by the emergence of new applications for synthetic biology across multiplexed diagnostics, cellular recording, and therapeutic genome editing, which are expected to significantly increase the demand for synthetic products over the coming years.
The adoption of synthetic biology is also rising in industries such as energy and chemicals, where synthetic biology-based products and processes are being integrated to enhance performance and sustainability. As these applications continue to broaden, the value and utility of synthetic biology are expected to grow correspondingly, supporting widespread market expansion.
The COVID-19 pandemic further accelerated the use of synthetic biology technologies. Over the past two years, leading pharmaceutical, biotechnology, and synthetic biology companies have intensified their research efforts, employing advanced techniques to develop COVID-19 test kits, treatments, and vaccines. A study by the European Parliament highlighted synthetic biology as a key emerging technology with potential applications in managing COVID-19 infections, while the U.S. National Institutes of Health emphasized its importance in speeding up vaccine development.
The increase in R&D efforts across diverse sectors is expected to generate substantial market growth. Companies are increasingly turning to synthetic biology methods to improve traditional biofuel production, enabling better efficiency and the use of low-cost raw materials such as waste products. Moreover, brands like Bolt Threads, Modern Meadow, and VitroLabs are utilizing biotechnology to create sustainable materials, demonstrating the broad applicability of synthetic biology across industries such as fashion, chemicals, and materials science.
Order a free sample PDF of the Synthetic Biology Market Intelligence Study, published by Grand View Research.
Key Market Trends & Insights
- Regional Insights: North America held the largest share of 41.98% in 2024, supported by substantial public and private investments, including significant contributions from venture capital and government programs. The region's strong research ecosystem, led by top universities and laboratories, continues to drive innovation. Rising demand for sustainable solutions in healthcare, agriculture, and energy further reinforces market growth.
- Product Insights: The enzymes segment dominated the market in 2024 with a 36.79% share. Enzymes are essential in biotechnological processes such as DNA manipulation, metabolic pathway engineering, and protein modification. Their critical roles in pharmaceuticals, agriculture, and biofuels—along with advancements in enzyme engineering—have strengthened their position in the market and will continue to support their growing adoption.
- Technology Insights: The PCR segment accounted for the largest share at 30.07% in 2024. Polymerase Chain Reaction remains a core technology for detecting and analyzing specific genes. Highly sensitive tools like real-time PCR assays are widely used in genomics, forensic analysis, and DNA cloning, supporting sustained demand.
- Application Insights: The healthcare segment led the market in 2024 due to its central role in developing advanced therapies and diagnostics. Innovations in gene editing, personalized medicine, and biopharmaceuticals have improved treatment options for both chronic and rare diseases. The growing emphasis on targeted therapies and efficient drug discovery—highlighted further during the COVID-19 pandemic—solidifies healthcare as the leading application area.
- End-use Insights: Biotechnology and pharmaceutical companies accounted for the largest revenue share at 54.92% in 2024. These organizations heavily rely on synthetic biology to create next-generation treatments such as gene therapies, monoclonal antibodies, and personalized medicines. Increased R&D investments and rising demand for high-efficiency vaccine development underline their dominant market role.
Market Size & Forecast
- 2024 Market Size: USD 16.2 Billion
- 2030 Projected Market Size: USD 42.06 Billion
- CAGR (2025-2030): 17.30%
- North America: Largest market in 2024
- Asia Pacific: Fastest growing market
Key Companies & Market Share Insights
Companies operating in the synthetic biology sector are expanding their capabilities by enhancing R&D, scaling production, and acquiring smaller firms to broaden their service offerings and strengthen market presence. These strategies are helping organizations diversify their technological portfolios and improve competitiveness within the rapidly evolving industry.
Key Players
- Bota Biosciences Inc.
- Codexis, Inc.
- Creative Biogene.
- Creative Enzymes.
- Enbiotix, Inc.
- Illumina, Inc.
- Merck Kgaa (Sigma-Aldrich Co. Llc)
- New England Biolabs
- Eurofins Scientific
- Novozymes
- Pareto Bio, Inc.
- Scarab Genomics, Llc
- Synthego
- Synthetic Genomics Inc.
- Thermo Fisher Scientific, Inc.
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion
The global synthetic biology market is set for strong growth, driven by expanding applications in healthcare, energy, chemicals, and materials science. Innovations in areas such as genome editing, enzyme engineering, and PCR-based technologies continue to shape the market landscape. The COVID-19 pandemic played a pivotal role in accelerating synthetic biology adoption, highlighting its potential to develop rapid diagnostics, vaccines, and advanced therapeutics. With North America leading the market and Asia Pacific emerging as the fastest-expanding region, increasing investments, supportive research initiatives, and cross-industry integration are expected to propel the market significantly through 2030.
No comments:
Post a Comment